{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:11:11Z","timestamp":1789603871146,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e36310","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T20:28:13Z","timestamp":1723580893000},"page":"e36310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early stoppage of empirical antibiotic therapy at clinical improvement in paediatric leukaemia patients with high-risk febrile neutropenia (ESAT-HR-FN study): Study protocol of a single centre investigator initiated randomised open label non-inferiority trial"],"prefix":"10.1016","volume":"10","author":[{"given":"Santhosh Kumar","family":"Kn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh Kumar","family":"Chellapuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvadeep","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak Kumar","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e36310_bib1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/383050","article-title":"Management of fever in neutropenic patients with different risks of complications","volume":"39","author":"Klastersky","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1556\/1886.2015.00021","article-title":"Evaluation of bloodstream infections during chemotherapy-induced febrile neutropenia in patients with malignant hematological diseases: single center experience","volume":"5","author":"Piukovics","year":"2015","journal-title":"Eur J Microbiol Immunol"},{"key":"10.1016\/j.heliyon.2024.e36310_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s15010-013-0468-1","article-title":"Bloodstream infections in patients with or without cancer in a large community hospital","volume":"41","author":"Bos","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.heliyon.2024.e36310_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4103\/0019-509X.175363","article-title":"Review of spectrum and sensitivity of bacterial bloodstream isolates in children with malignancy: a retrospective analysis from a single center","volume":"51","author":"Reddy","year":"2014","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib5","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s12032-011-9858-3","article-title":"Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India","volume":"29","author":"Ghosh","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s12032-009-9330-9","article-title":"Infections in acute myeloid leukemia: an analysis of 382 febrile episodes","volume":"27","author":"Gupta","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/pbc.22582","article-title":"Fatality in febrile neutropenia due to H1N1 influenza: an alert for pediatric oncologists","volume":"55","author":"Ghosh","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/adc.87.6.541","article-title":"Acute encephalopathy with parvovirus B19 infection in sickle cell disease","volume":"87","author":"Bakhshi","year":"2002","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.heliyon.2024.e36310_bib9","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/pbc.23229","article-title":"Dengue fever in patients with pediatric malignancy on chemotherapy: a concern in tropical countries","volume":"57","author":"Bahl","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib10","first-page":"971","article-title":"H1N1 infection in children with hematological malignancies","volume":"48","author":"Malik","year":"2011","journal-title":"Indian Pediatr."},{"key":"10.1016\/j.heliyon.2024.e36310_bib11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/INF.0b013e31821dc991","article-title":"Visceral leishmaniasis as a cause of persistent fever in pediatric hodgkin lymphoma","volume":"30","author":"Pani","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.heliyon.2024.e36310_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/INF.0b013e31819f3d29","article-title":"Acanthamebic meningoencephalitis presenting as personality change","volume":"28","author":"Radhakrishnan","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.heliyon.2024.e36310_bib13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/pbc.21477","article-title":"Successful treatment of acanthamoeba meningoencephalitis during induction therapy of childhood acute lymphoblastic leukemia","volume":"50","author":"Gupta","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia","volume":"328","author":"Wood","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36310_bib15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jiph.2018.12.006","article-title":"Epidemiology and source of infection in patients with febrile neutropenia: a ten-year longitudinal study","volume":"12","author":"Al-Tawfiq","year":"2019","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.heliyon.2024.e36310_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/OP.21.00148","article-title":"Risk-stratifying treatment strategies for febrile neutropenia\u2014tools, tools everywhere, and not a single one that works?","volume":"17","author":"Wijeratne","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.heliyon.2024.e36310_bib17","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1200\/JCO.22.02224","article-title":"Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update","volume":"41","author":"Lehrnbecher","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00043426-200201000-00011","article-title":"Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer","volume":"24","author":"Alexander","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib19","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.ejca.2009.06.003","article-title":"Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting","volume":"45","author":"Dommett","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199907293410501","article-title":"A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy","volume":"341","author":"Freifeld","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36310_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO;2-D","article-title":"Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial","volume":"85","author":"Hidalgo","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjc.6600993","article-title":"Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study","volume":"89","author":"Innes","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12098-020-03377-x","article-title":"Early discontinuation versus continuation of antimicrobial therapy in low risk pediatric cancer patients with febrile neutropenia, before recovery of counts: a randomized controlled trial (dalfen study)","volume":"88","author":"Kumar","year":"2021","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.heliyon.2024.e36310_bib24","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib25","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib26","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1200\/JCO.22.02224","article-title":"Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update","volume":"41","author":"Lehrnbecher","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib27","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(22)00145-4","article-title":"Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial","volume":"9","author":"De Jonge","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.heliyon.2024.e36310_bib28","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2001.19.14.3415","article-title":"Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever","volume":"19","author":"Santolaya","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib29","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/cancers15051611","article-title":"Systematic review of the short-term versus long-term duration of antibiotic management for neutropenic fever in patients with cancer","volume":"15","author":"Ishikawa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e36310_bib30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/1097-0142(197310)32:4<1007::AID-CNCR2820320437>3.0.CO;2-M","article-title":"Management of fever of unknown origin in patients with neoplasms and neutropenia","volume":"32","author":"Rodriguez","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0002-9343(79)90390-5","article-title":"Duration of empiric antibiotic therapy in granulocytopenic patients with cancer","volume":"67","author":"Pizzo","year":"1979","journal-title":"Am. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36310_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36310_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/514500","article-title":"Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study","volume":"25","author":"Santolaya","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00043426-200009000-00004","article-title":"Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia","volume":"22","author":"Klaassen","year":"2000","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cmi.2016.11.001","article-title":"Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial","volume":"23","author":"Santolaya","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.heliyon.2024.e36310_bib36","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.heliyon.2024.e36310_bib37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.heliyon.2024.e36310_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e36310_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13063-022-06033-1","article-title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India","volume":"23","author":"Das","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.heliyon.2024.e36310_bib40","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib41","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e36310_bib42","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36310_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28404","article-title":"Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: a prospective, phase II study","volume":"67","author":"Garg","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib44","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12288-020-01377-7","article-title":"Surveillance stool culture and its association with microbiologically documented infection during febrile neutropenia in patients with acute leukemia (AL) undergoing induction chemotherapy","volume":"37","author":"Jadhav","year":"2021","journal-title":"Indian J Hematol Blood Transfus Off J Indian Soc Hematol Blood Transfus"},{"key":"10.1016\/j.heliyon.2024.e36310_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100855","article-title":"Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML\/MDS (safe study): a retrospective comparative cohort study","volume":"35","author":"Schauwvlieghe","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.heliyon.2024.e36310_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-023-08058-6","article-title":"Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country","volume":"23","author":"Joudeh","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cncr.21115","article-title":"Risk factors for infections with multidrug\u2010resistant Pseudomonas aeruginosa in patients with cancer","volume":"104","author":"Ohmagari","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib49","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1086\/323895","article-title":"Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices","volume":"33","author":"Singh","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib50","doi-asserted-by":"crossref","first-page":"e4521","DOI":"10.1093\/cid\/ciaa1464","article-title":"Changing epidemiology and decreased mortality associated with carbapenem-resistant gram-negative bacteria, 2000\u20132017","volume":"73","author":"Babiker","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4103\/jgid.jgid_101_17","article-title":"Rectal carriage of carbapenem-resistant enterobacteriaceae: a menace to highly vulnerable patients","volume":"10","author":"Kumar","year":"2018","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-021-01415-y","article-title":"Intestinal colonization due to carbapenem-resistant enterobacteriaceae among hematological malignancy patients in India: prevalence and molecular charecterisation","volume":"38","author":"Kumar","year":"2022","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.heliyon.2024.e36310_bib53","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.bbmt.2020.07.011","article-title":"Anaerobic antibiotics and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Tanaka","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e36310_bib54","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1016\/j.cell.2022.09.007","article-title":"Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease","volume":"185","author":"Hayase","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e36310_bib55","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib56","series-title":"Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients","year":"2012"},{"key":"10.1016\/j.heliyon.2024.e36310_bib57","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e36310_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/QCO.0b013e32833ef7d1","article-title":"New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients","volume":"23","author":"Chen","year":"2010","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e36310_bib59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jiac.2014.11.008","article-title":"Detection of bacteria and fungi in blood of patients with febrile neutropenia by real-time PCR with universal primers and probes","volume":"21","author":"Teranishi","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.heliyon.2024.e36310_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27887","article-title":"Updated systematic review and meta\u2010analysis of the predictive value of serum biomarkers in the assessment and management of fever during neutropenia in children with cancer","volume":"66","author":"Arif","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.heliyon.2024.e36310_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.828569","article-title":"Biomarkers for diagnosing febrile illness in immunocompromised children: a systematic review of the literature","volume":"10","author":"Van Der Velden","year":"2022","journal-title":"Front Pediatr"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:52:41Z","timestamp":1773183161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024123419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":61,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024123419"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36310","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early stoppage of empirical antibiotic therapy at clinical improvement in paediatric leukaemia patients with high-risk febrile neutropenia (ESAT-HR-FN study): Study protocol of a single centre investigator initiated randomised open label non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36310"}}